LivaNova (NASDAQ:LIVN) Downgraded to “Buy” Rating by StockNews.com

StockNews.com cut shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning.

Several other brokerages also recently issued reports on LIVN. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Mizuho lowered their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday. Needham & Company LLC lowered their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus lowered their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $64.20.

LivaNova Trading Down 0.6 %

Shares of LIVN opened at $41.45 on Wednesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.25 billion, a P/E ratio of 98.69 and a beta of 1.00. The stock’s fifty day simple moving average is $47.65 and its 200 day simple moving average is $49.56. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Several large investors have recently modified their holdings of LIVN. Nordea Investment Management AB lifted its position in shares of LivaNova by 22.2% during the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after purchasing an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in shares of LivaNova during the fourth quarter worth about $1,954,000. KBC Group NV lifted its position in shares of LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after purchasing an additional 56,580 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of LivaNova by 38.3% during the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of LivaNova during the third quarter worth about $529,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.